SOURCE: Tauriga Sciences, Inc.

Tauriga Sciences, Inc.

December 07, 2016 07:45 ET

Tauriga Sciences, Inc. Reports Progress in Completing the Formulation of its First ColluMauxil Branded Product, a Cannabidiol "CBD" Infused Roll On for Muscle Tension Relief

LOS ANGELES, CA--(Marketwired - Dec 7, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a company engaged in building businesses in the life sciences space, has today announced that the Company has completed the formulation of RolLeaf, its proprietary CBD infused product targeting individuals who suffer from muscle tension. The Company has manufactured its first sample batch of the product. As previously disclosed, the Company is forming a new subsidiary called ColluMauxil Therapeutics LLC ("ColluMauxil") to focus on the development, marketing, and licensing of non-opioid products and product lines that specifically target muscle tension, a key component of pain.

The Company has done extensive market research to identify the most commercially important product specifications and guidelines for this large unmet need. According to the American Pain Society, pain is the most common reason that people seek medical care, yet pain management is generally inadequate for chronic pain.

On Monday December 5, 2016, the Company created its first sample batch of RolLeaf, its muscle tension product, at a Southern California based analytical laboratory. A key ingredient of the product is CBD isolate, which is 99+% pure, anhydrous (crystalline) Cannabidiol that is extracted from hemp. Because the Company's formula utilizes 99+% pure CBD isolate that contains no THC, the product is legal in all 50 states, South America, Europe and Australia.

Incorporating the feedback of multiple distributors and potential retail customers, the Company has designed its product line with a roll-on delivery system. Two initial volume sizes have been established for the product launch. The Company created a 3 oz. unit, as that volume can be transported by carry on airplane passengers in the United States. Additionally the Company created a 10 ml sample size product that will be used at investor presentations, in store promotional activities, doctors' offices, and with potential distributors.

The Company has set its corporate goal to finalize the CBD infused pain roll-on product, including RolLeaf's final packaging (inclusive of logo and graphics) on or before December 31, 2016. If the Company is successful in achieving that milestone, there is the potential of generating revenue during the 1st calendar quarter of 2017 (January 1, 2017 - March 31, 2017). However, there can be no guarantee that revenue will be achieved during that time period or at all.

Tauriga's CEO Seth Shaw expressed, "The Company has been working hard to establish and formulate a high quality roll-on product based upon stringent guidelines and market demand. In order to design the best product for consumers and to position it for commercial success, the Company has been in continual contact and discussions with potential distributors and customers as well as with technical advisors. We are grateful to all these people for their valuable input, including the Company's previous CEO, Dr. Stella Sung."

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is a life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company's previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Platintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it's seeking monetary damages in excess of $4,000,000 USD.

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation: expectations, expects, anticipates, believes, hopes, beliefs, plans and objectives regarding the development, use and marketability of products as well as the attainment of certain corporate goals and milestones (i.e. SEC Periodic Filings, Filing of Proxies, etc.). Such forward-looking statements are based on present circumstances and on Tauriga's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Tauriga has little or no control. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by Tauriga with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Contact Information

  • Contact:
    Tauriga Sciences, Inc.
    Mr. Seth Shaw
    Chief Executive Officer
    Tel: 1-917-796-9926
    Email: sshaw@tauriga.com